RESULTS
The study included 6395 liveborn pregnancy-child dyads with data on
child ADHD (sample I); of these, 2395 had available mother-reported data
on ADHD symptoms by child age 5 years (sample II) (Figure S1). Few women
(2.5-3.2%) participated with more than one pregnancy in both samples.
The majority of women (80.0-81.8%) reported non-medicated clinical
depression/anxiety during pregnancy, and 12.8-13.4% (n=818 in sample I,
n=320 in sample II) were taking SSRI/SNRI prenatally, mainly as
monotherapy. Of the SSRI/SNRI exposed, 789 (96.5%) reported such use
for the indication of depression and/or anxiety, and 30 (3.7%) were on
polytherapy with another antidepressant (mainly mirtazapine or a
tricyclic antidepressant). Baseline maternal and paternal
sociodemographic, life-style and health characteristics, as well as
selected child correlates by ever use of SSRI/SNRI in pregnancy, are
shown in Table 1 (sample I) and Table S3 (sample II).